HIF1A and cancer: With this preclinical background, we designed in the SFCE (Société Française des Cancers de l’Enfant) committee of new drugs and pharmacology a phase I study in pediatric refractory or recurrent cancers with increasing doses of rapamycin and irinotecan to target in concomitantly mTorc1 and HIF-1α.